SK Biopharma (326030.KS) Q1 2026: Cenobamate Lifts Operating Profit 250%, Margin Hits 39%
Single-drug operating leverage transforms SK Biopharmaceuticals from loss-making drug launcher to high-margin cash generator — operating margin more than doubles year-over-year.
Source: Q1 2026 Quarterly Report (16th Fiscal Year) — Filed May 15, 2026 with DART | Consolidated Financial Statements | Unit: ₩ billions
“SK Biopharma (326030.KS) Q1 2026: Cenobamate Lifts Operating Profit 250%, Margin Hits 39%”
This article became available on June 13, 2026. Subscribe to read in full, or wait until September 11, 2026 when it becomes free.
Cancel anytime. Full refund within 7 days.
You just read what happened. Here's how to read what it means.
We read SK Biopharma's latest DART filing in full — financials under K-IFRS, governance, and what it means for the stock. PDF in your inbox in 30–40 min.
$12 · one-time
Get the SK Biopharma reportReading several Korean stocks a week? Get on-demand analysis on any KOSPI or KOSDAQ company, whenever you need it.
$9.99 · monthly
SubscribeIndependent journalism based on primary DART filings — not investment advice. No brokerage affiliation.
